Evidence map›Paper›PMID 42502496›Full record

ArticleAAPS open2026

Drying stability and permeability advantages of amorphous drug nanoparticles.

Akshay Narula, Ajay Lale, Paroma Chakravarty, Na Li

Abstract read
In one paragraph

Article in AAPS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Akshay Narula *Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road Unit 3092, Storrs, CT 06269 USA.
Ajay Lale *Department of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road Unit 3092, Storrs, CT 06269 USA.
Paroma ChakravartySynthetic Molecule Pharmaceutical Sciences, Genentech, Inc., San Francisco, CA 94080 USA.
Na LiDepartment of Pharmaceutical Sciences, University of Connecticut, 69 North Eagleville Road Unit 3092, Storrs, CT 06269 USA.ORCID 0000-0001-8941-4784

Funding

Enabling oral drug formulations: mechanistic studies and modelingR35GM155235 · NIGMS · UNIVERSITY OF CONNECTICUT STORRS · PI Na Li · 2024 to 2026
$1.2M
NIGMS NIH HHS R35 GM155235
6 · The paper itself

Abstract

The objective of this study was to develop stable amorphous drug nanoparticles with high drug loading and bioavailability advantages to overcome the drug-loading limitations of conventional amorphous solid dispersion (ASD) formulations. Amorphous drug nanoparticles were prepared Graphical Abstract: Supplementary Information: The online version contains supplementary material available at 10.1186/s41120-026-00185-z.

Indexed as

Amorphous nanoparticlesDryingIonic interactionsStabilizer

Identifiers

PMID42502496
PMCPMC13400673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.